Arcturus Therapeutics Holdings Inc. (ARCT) financial statements (2022 and earlier)

Company profile

Business Address 10628 SCIENCE CENTER DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments370,492462,89571,353
Cash and cash equivalents370,492462,89571,353
Receivables3,3672,1252,179
Other undisclosed current assets5,1022,769758
Total current assets:378,961467,78974,290
Noncurrent Assets
Operating lease, right-of-use asset5,6185,1825,134
Property, plant and equipment5,6433,3782,349
Long-term investments and receivables515 263
Long-term investments515 263
Restricted cash and investments2,077107107
Total noncurrent assets:13,8538,6677,853
TOTAL ASSETS:392,814476,45682,143
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities33,58131,41312,927
Accounts payable10,05810,7745,793
Accrued liabilities23,52320,6397,134
Deferred revenue43,48218,1088,397
Debt22,474  
Total current liabilities:99,53749,52121,324
Noncurrent Liabilities
Long-term debt and lease obligation45,13517,87019,845
Long-term debt, excluding current maturities40,63313,84514,995
Operating lease, liability4,5024,0254,850
Liabilities, other than long-term debt19,93112,51215,182
Deferred revenue19,93112,51215,182
Total noncurrent liabilities:65,06630,38235,027
Total liabilities:164,60379,90356,351
Stockholders' equity
Stockholders' equity attributable to parent228,211396,55325,792
Common stock262615
Additional paid in capital575,675540,34397,445
Accumulated deficit(347,490)(143,816)(71,668)
Total stockholders' equity:228,211396,55325,792
TOTAL LIABILITIES AND EQUITY:392,814476,45682,143

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Revenues12,3599,53920,789
Gross profit:12,3599,53920,789
Operating expenses(215,211)(81,063)(46,302)
Operating loss:(202,852)(71,524)(25,513)
Nonoperating expense(1,337)(361)(446)
Foreign currency transaction gain, before tax584  
Other nonoperating expense(1,921)(361)(446)
Interest and debt expense(2,700)(900)(900)
Loss from continuing operations before equity method investments, income taxes:(206,889)(72,785)(26,859)
Income (loss) from equity method investments515(263)(32)
Net loss:(206,374)(73,048)(26,891)
Other undisclosed net income attributable to parent2,700900900
Net loss available to common stockholders, diluted:(203,674)(72,148)(25,991)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Net loss:(206,374)(73,048)(26,891)
Comprehensive loss:(206,374)(73,048)(26,891)
Other undisclosed comprehensive income, net of tax, attributable to parent2,700900900
Comprehensive loss, net of tax, attributable to parent:(203,674)(72,148)(25,991)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: